BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35850914)

  • 21. Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.
    Blijlevens M; Li J; van Beusechem VW
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splicing to Keep Cycling: The Importance of Pre-mRNA Splicing during the Cell Cycle.
    Petasny M; Bentata M; Pawellek A; Baker M; Kay G; Salton M
    Trends Genet; 2021 Mar; 37(3):266-278. PubMed ID: 32950269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defects in spliceosomal machinery: a new pathway of leukaemogenesis.
    Maciejewski JP; Padgett RA
    Br J Haematol; 2012 Jul; 158(2):165-173. PubMed ID: 22594801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
    Dvinge H; Guenthoer J; Porter PL; Bradley RK
    Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.
    Ogiya D; Chyra Z; Verselis SJ; O'Keefe M; Cobb J; Abiatari I; Talluri S; Sithara AA; Hideshima T; Chu MP; Hájek R; Dorfman DM; Pilarski LM; Anderson KC; Adamia S
    Blood Cancer J; 2023 Feb; 13(1):23. PubMed ID: 36737429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles and mechanisms of alternative splicing in cancer - implications for care.
    Bonnal SC; López-Oreja I; Valcárcel J
    Nat Rev Clin Oncol; 2020 Aug; 17(8):457-474. PubMed ID: 32303702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Function, clinical application, and strategies of Pre-mRNA splicing in cancer.
    Di C; Syafrizayanti ; Zhang Q; Chen Y; Wang Y; Zhang X; Liu Y; Sun C; Zhang H; Hoheisel JD
    Cell Death Differ; 2019 Jul; 26(7):1181-1194. PubMed ID: 30464224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.
    Wojtuszkiewicz A; Assaraf YG; Maas MJ; Kaspers GJ; Jansen G; Cloos J
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):673-89. PubMed ID: 25495223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
    Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
    Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
    Taylor J; Lee SC
    Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
    Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA splicing dysregulation and the hallmarks of cancer.
    Bradley RK; Anczuków O
    Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spliceosome mutations in hematopoietic malignancies.
    Hahn CN; Scott HS
    Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.
    Adamia S; Kriangkum J; Belch AR; Pilarski LM
    Adv Cancer Res; 2014; 123():67-94. PubMed ID: 25081526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational determinants of epigenetic instablity in myeloid malignancies.
    Jankowska AM; Szpurka H
    Semin Oncol; 2012 Feb; 39(1):80-96. PubMed ID: 22289495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-cancer analysis identifies mutations in
    Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
    Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations of RNA splicing factors in hematological malignancies.
    Shukla GC; Singh J
    Cancer Lett; 2017 Nov; 409():1-8. PubMed ID: 28888996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA splicing, cell signaling, and response to therapies.
    Abou Faycal C; Gazzeri S; Eymin B
    Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.